| 000 | 01815 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517112333.0 | ||
| 264 | 0 | _c20170726 | |
| 008 | 201707s 0 0 eng d | ||
| 022 | _a1873-5835 | ||
| 024 | 7 |
_a10.1016/j.leukres.2016.07.004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRavandi, Farhad | |
| 245 | 0 | 0 |
_aA phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). _h[electronic resource] |
| 260 |
_bLeukemia research _c09 2016 |
||
| 300 |
_a92-100 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aCytarabine _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-mdm2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGojo, Ivana | |
| 700 | 1 | _aPatnaik, Mrinal M | |
| 700 | 1 | _aMinden, Mark D | |
| 700 | 1 | _aKantarjian, Hagop | |
| 700 | 1 | _aJohnson-Levonas, Amy O | |
| 700 | 1 | _aFancourt, Craig | |
| 700 | 1 | _aLam, Raymond | |
| 700 | 1 | _aJones, Mary Beth | |
| 700 | 1 | _aKnox, Clayton D | |
| 700 | 1 | _aRose, Shelonitda | |
| 700 | 1 | _aPatel, Payal Shah | |
| 700 | 1 | _aTibes, Raoul | |
| 773 | 0 |
_tLeukemia research _gvol. 48 _gp. 92-100 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.leukres.2016.07.004 _zAvailable from publisher's website |
| 999 |
_c26345414 _d26345414 |
||